EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical application and drug resistance mechanism of gemcitabine

Xuanrui Zhang, Bing Qi, Jing Chen

Frontiers in Cell and Developmental Biology · 10.11.2025 · 13

DOI: 10.3389/fcell.2025.1702720 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 10.11.2025. Verfasst von Xuanrui Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine, as a nucleoside analog, exerts a broad-spectrum antitumor effect by interfering with DNA synthesis, but its clinical application is limited by drug resistance. The drug resistance mechanism involves metabolic abnormalities (such as downregulation of deoxycytidine kinase (dCK), nucleoside transporter hENT1 deficiency), enhanced DNA repair (overexpression of ribonucleotide reductase ribonucleotide reductase catalytic subunit M1 (RRM1)/ribonucleotide reductase catalytic subunit M2 (RRM2), and tumor microenvironment remodeling (such as secretion of immunosuppressive factors by CAFs). This article systematically reviews the drug resistance mechanism of gemcitabine and explores the breakthrough direction of new drug delivery systems (liposomes, albumin nanoparticles) and combination therapy strategies (targeted drugs, immune checkpoint inhibitors). In addition, cutting-edge technologies such as single-cell sequencing and artificial intelligence drug sensitivity prediction provide a new paradigm for precision treatment. In the future, it is necessary to build a “prevention-monitoring-intervention” full-chain management system through dynamic monitoring of multi-omics biomarkers (such as circulating tumor DNA tracking RRM2 amplification) and coordinated intervention of traditional Chinese and Western medicine (such as curcumin reversing drug resistance).

Schlagwörter

Stichwörter der Autor:innen

combination therapygemcitabineprecision medicineresistance mechanismtumor microenvironment

Autor:innen und Institutionen

  • College of Life Sciences, North China University of Science and Technology, Tangshan, Hebei, China.

Zitieren

APA

Zhang, X., Qi, B., & Chen, J. (2025). Clinical application and drug resistance mechanism of gemcitabine. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1702720

Vancouver

Zhang X, Qi B, Chen J. Clinical application and drug resistance mechanism of gemcitabine. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1702720

BibTeX
@article{Zhang2025,
  author = {Zhang, Xuanrui and Qi, Bing and Chen, Jing},
  title = {Clinical application and drug resistance mechanism of gemcitabine},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1702720}
}
Kostenlos starten →